Shots:

• Artax has concluded the patient enrollment under the P-IIa clinical evaluation of AX-158 (FIC Nck modulator) to treat autoimmune indications
• The P-IIa proof-of-mechanism trial will assess the safety & efficacy of AX-158 single dose vs PBO for treating patients (n=30) with mild to moderate plaque psoriasis, in ratio 2:1, for 28 days and another 30 days for safety across the UK. Topline data is anticipated in Q4’24
• AX-158 demonstrated strong cytokine modulation & therapeutic efficacy in murine models of self-antigen activation as well as extended PD effect, indicating immune effect. Signs of activity in Th2, Th17, Th1/Th0 pathways were observed, suggesting broad application in autoimmune diseases